Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Chi Ieong Lei"'
Publikováno v:
Chinese Medicine, Vol 16, Iss 1, Pp 1-16 (2021)
Abstract Background The National Medical Products Administration (NMPA) in China has set to advance the regulatory capacity of traditional Chinese medicines (TCMs) with the adoption of regulatory science (RS). However, the priority of actions at the
Externí odkaz:
https://doaj.org/article/f83c8873ced44c1487d7a057f379e912
Publikováno v:
Frontiers in Public Health, Vol 9 (2021)
Introduction: The role of pharmacists in public health management is expected to grow into a key player in the continuing measures of managing the COVID-19 pandemic, especially in the community setting. However, their intention to provide essential p
Externí odkaz:
https://doaj.org/article/d2f15588e3b343808e4e92e934c354fe
Autor:
Jiatong Li, Jianfan Zhu, Hao Hu, Joanna E. Harnett, Chi Ieong Lei, Ka Yin Chau, Ging Chan, Carolina Oi Lam Ung
Publikováno v:
Chinese Medicine, Vol 13, Iss 1, Pp 1-15 (2018)
Abstract Internationalization of Traditional/Complementary Medicine (T&CM) products is important for initiating and sustaining developments in this field. Particularly for traditional Chinese medicines (TCMs), the global market continues to expand du
Externí odkaz:
https://doaj.org/article/fa69197c04ea42cea3b2988dcdcc96ea
Publikováno v:
Frontiers in Public Health
Frontiers in Public Health, Vol 9 (2021)
Frontiers in Public Health, Vol 9 (2021)
Introduction: The role of pharmacists in public health management is expected to grow into a key player in the continuing measures of managing the COVID-19 pandemic, especially in the community setting. However, their intention to provide essential p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46d7b82a340746400338271811745ea7
https://doi.org/10.3389/fpubh.2021.653335
https://doi.org/10.3389/fpubh.2021.653335
Publikováno v:
Chinese Medicine
Chinese Medicine, Vol 16, Iss 1, Pp 1-16 (2021)
Chinese Medicine, Vol 16, Iss 1, Pp 1-16 (2021)
Background The National Medical Products Administration (NMPA) in China has set to advance the regulatory capacity of traditional Chinese medicines (TCMs) with the adoption of regulatory science (RS). However, the priority of actions at the interface
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c55aeed06d036f424076496f533209e
http://europepmc.org/articles/PMC7884970
http://europepmc.org/articles/PMC7884970
Autor:
Jianfan Zhu, Jiatong Li, Joanna Harnett, Carolina Oi Lam Ung, Hao Hu, Ka Yin Chau, Chi Ieong Lei, Ging Chan
Publikováno v:
Chinese Medicine, Vol 13, Iss 1, Pp 1-15 (2018)
Chinese Medicine
Chinese Medicine
Internationalization of Traditional/Complementary Medicine (T&CM) products is important for initiating and sustaining developments in this field. Particularly for traditional Chinese medicines (TCMs), the global market continues to expand due to an i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b94ee1c72d44b722286d8cc283c6c8c
http://link.springer.com/article/10.1186/s13020-018-0209-6
http://link.springer.com/article/10.1186/s13020-018-0209-6